Autoimmune polyendocrine syndrome type 2

Autoimmune Polyendocrine Syndrome Type 2 (APS-2), also known as Schmidt's syndrome, is a complex autoimmune disorder characterized by the coexistence of at least two autoimmune diseases, including Addison's disease, thyroid autoimmune diseases (such as Graves' disease or Hashimoto's thyroiditis), and type 1 diabetes mellitus. This syndrome is more common in females and typically presents in adulthood.

Etiology and Pathogenesis

The exact cause of APS-2 is unknown, but it is believed to involve a combination of genetic predisposition and environmental factors. The HLA-DQ gene is often associated with the syndrome, suggesting a strong genetic component. Environmental triggers may include viral infections, stress, and other unknown factors that initiate an autoimmune response in genetically susceptible individuals.

Clinical Manifestations

APS-2 presents with a variety of symptoms depending on the specific autoimmune diseases involved. Common manifestations include:

• Addison's disease symptoms: fatigue, weight loss, skin hyperpigmentation, low blood pressure, and salt craving.
• Thyroid autoimmune diseases symptoms: depending on whether the patient has Graves' disease (hyperthyroidism) or Hashimoto's thyroiditis (hypothyroidism), symptoms can include weight changes, mood swings, heat or cold intolerance, and changes in heart rate.
• Type 1 diabetes mellitus symptoms: increased thirst and urination, weight loss, fatigue, and blurred vision.

Diagnosis

Diagnosis of APS-2 involves a combination of clinical evaluation and laboratory tests. Key diagnostic tests include:

• Autoantibody tests: to detect antibodies against the adrenal cortex, thyroid, and pancreatic islet cells.
• Hormone level tests: to assess the function of the affected glands (e.g., cortisol, thyroid hormones, and insulin).
• Imaging studies: such as ultrasound or CT scans, may be used to evaluate the structure of the thyroid gland and adrenal glands.

Treatment

Treatment of APS-2 focuses on managing the symptoms of the individual autoimmune diseases involved and may require a multidisciplinary approach. Common treatments include:

• Corticosteroids: for Addison's disease to replace the deficient hormones.
• Thyroid hormone replacement therapy: for Hashimoto's thyroiditis.
• Antithyroid drugs or radioactive iodine therapy: for Graves' disease.
• Insulin therapy: for type 1 diabetes mellitus.

Regular monitoring and adjustments of therapy are essential due to the progressive nature of these autoimmune diseases.

Prognosis

With appropriate treatment and monitoring, individuals with APS-2 can manage their symptoms and maintain a relatively normal quality of life. However, they must remain vigilant for the development of additional autoimmune diseases.

Epidemiology

APS-2 is less common than Autoimmune Polyendocrine Syndrome Type 1 (APS-1) but is more prevalent in certain populations, particularly those of Northern European descent. It typically presents in adulthood, with a higher incidence in females.

See Also

• Autoimmune Polyendocrine Syndrome Type 1
• Autoimmune disease
• Endocrine system

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian